All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Andrew Brunner, Massachusetts General Hospital, Boston, US. We asked, What new treatments are available for high-risk myelodysplastic syndromes (MDS)? What does this mean for patients?
What new treatments are available for high-risk MDS? What does this mean for patients?
In this video, Brunner discusses novel treatment options available for high-risk MDS and the the implications for patients. He also discusses the findings from an ongoing phase II and III trial (NCT03066648), investigating the efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with high-risk MDS.
Sabatolimab for the treatment of poor prognosis myelodysplastic syndromes and acute myeloid leukemia
High-risk and very high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) carry poor prognosis for patients despite advances in...
Why is TIM-3 a good target for treating patients with high-risk MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Andrew M. Brunner, Massachusetts General Hospital, Boston, US. We asked, Why...
Subscribe to get the best content related to MDS delivered to your inbox